PRKACB and breast cancer: Given that low expression of PRKACB has been demonstrated leading to unfavorable clinical outcomes in patients undergoing breast cancer and colorectal carcinoma (54, 77), we speculate that the low expression of PRKACB may contribute to the occurrence and development of OS, thereby bringing about inferior clinical outcomes.